Pharmacotherapeutic management of lower urinary tract symptoms

Aurora Zanghì, Sebastiano Cimino, Daniele Urzì, Salvatore Privitera, Francesco Zagari, Giuseppe Lanza, Francesco Patti, Emanuele D’Amico

Research output: Contribution to journalReview articlepeer-review


Introduction: Multiple Sclerosis (MS) manifests with a plethora of signs and symptoms affecting brain structures and spinal pathways. The multitude of lesions in MS patients makes difficult to establish the relative role of each of them to lower urinary tract symptoms (LUTS). Generally, the subcortical white-matter lesions result in detrusor overactivity, whilst lesions of the spinal cord result in the combined occurrence of detrusor overactivity and detrusor-sphincter dyssynergia (DSD). It has been estimated that 80–90% of patients with MS will suffer from some form of LUTS over the course of the disease. Among LUTS, the most reported is detrusor overactivity which includes urinary urgency, frequent urination, nocturia, and urge urinary incontinence. Areas covered: The authors review the management of lower urinary tract symptoms in MS patients providing their expert opinions on the subject matter. Expert opinion: LUTS affect the quality of life substantially and are associated with a significantly increased mortality. The adequate management is an important challenge for both patients and caregivers with a multidisciplinary approach likely necessary.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
Publication statusAccepted/In press - 2020


  • multidisciplinary approach
  • Multiple sclerosis
  • therapeutic management
  • urinary dysfunction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacotherapeutic management of lower urinary tract symptoms'. Together they form a unique fingerprint.

Cite this